Sign in to view content

Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results of the Phase 3 YOSEMITE and RHINE Trials

David A. Eichenbaum, MD, FASRS

Video
Published 2022

Related

Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022
Faricimab in Neovascular Age-Related Macular Degeneration: Week 48 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Karl G. Csaky, MD, PhD
Updates from the Field
2021
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Annual Meeting Talks
2022

Category: Diabetic Retinopathy

See more